AzTrials
AzTrials

AsthmaPhase 4NCT00363480

Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data

A Phase 4 study testing Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg and DISKUS™ powder inhalers in people with Asthma, run by GlaxoSmithKline at 32 sites in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC)… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Asthma
What is being tested?
Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg and DISKUS™ powder inhalers
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
221 participants
Where
32 sitesGermany
Study dates
17 May 2006to 14 Sep 2007
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of asthma
  • Reversibility >12% after inhalation of 200 µg Salbutamol
  • willingness and ability to complete daily record card on daily basis and to measure morning PEF on daily basis
  • 80% compliance in diary card completion asthma control status: Uncontrolled based on the GOAL criteria

Who cannot join

  • Change of asthma medication during the last 4 weeks
  • Asthma exacerbation characterized by use of oral corticoids during the last 3 months Pretreatment with inhaled corticosteroids more than 500 mcg Beclometasondipropionat or equivalent per day or other controller therapy during the last 3 months
  • upper or lower respiratory tract infection during the RUN-IN period moderate or severe asthma exacerbation during the RUN-IN period
  • Non compliance with use of Discus, PEF-meter and incomplete diary card data

Trial locations and contacts

32 sites in 1 country.

32 sites in 1 country

Germany32 sites
  • GSK Investigational Site

    Bad Arolsen, Hesse, 34454

  • GSK Investigational Site

    Berlin, 10367

  • GSK Investigational Site

    Berlin, 10717

  • GSK Investigational Site

    Berlin, 10965

  • GSK Investigational Site

    Berlin, 12165

  • GSK Investigational Site

    Berlin, 12687

  • GSK Investigational Site

    Berlin, 13187

  • GSK Investigational Site

    Berlin, 13597

  • GSK Investigational Site

    Braunschweig, Lower Saxony, 38100

  • GSK Investigational Site

    Buchholz, Lower Saxony, 21244

  • GSK Investigational Site

    Chemnitz, Saxony, 09126

  • GSK Investigational Site

    Cottbus, Brandenburg, 03050

  • GSK Investigational Site

    Dresden, Saxony, 01099

  • GSK Investigational Site

    Erlangen, Bavaria, 91052

  • GSK Investigational Site

    Eschwege, Hesse, 37269

  • GSK Investigational Site

    Geesthacht, Schleswig-Holstein, 21502

  • GSK Investigational Site

    Greiz, Thuringia, 07973

  • GSK Investigational Site

    Hamburg, 22767

  • GSK Investigational Site

    Hanover, Lower Saxony, 30159

  • GSK Investigational Site

    Hanover, Lower Saxony, 30167

  • GSK Investigational Site

    Kassel, Hesse, 34117

  • GSK Investigational Site

    Kassel, Hesse, 34121

  • GSK Investigational Site

    Kaufbeuren, Bavaria, 87600

  • GSK Investigational Site

    Landsberg am Lech, Bavaria, 86899

  • GSK Investigational Site

    Marburg, Hesse, 35037

  • GSK Investigational Site

    Munich, Bavaria, 80335

  • GSK Investigational Site

    Munich, Bavaria, 81677

  • GSK Investigational Site

    Rednitzhembach, Bavaria, 91126

  • GSK Investigational Site

    Sonneberg, Thuringia, 96515

  • GSK Investigational Site

    Uttenreuth, Bavaria, 91080

  • GSK Investigational Site

    Wedel, Free and Hanseatic City of Hamburg, 22880

  • GSK Investigational Site

    Würzburg, Bavaria, 97070

Other trials in Germany

About this study

Official title: Asthma Control Assessment Via ACT and DRC in Asthmatics Treated With Seretide (50/250) Over 12 Weeks

The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC) 50/250 µg twice daily. The asthma control test (ACT) will be used to detect differences in the level of asthma control during treatment. The study aims to show a correlation between improvements of ACT und the level of asthma control which will be reached by the patients.

The aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with SFC. We get information about ACT in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. Correlations are expected between the improvements in ACT, Quality of Life and asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.

Conditions
Asthma
Being tested
Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg, DISKUS™ powder inhalers
Keywords
Asthma, Asthma Control Test, SERETIDE
Medical subject headings
Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Salmeterol/Fluticasone 50/250 mcgDrug

    Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.

  • Salbutamol 100 mcgDrug

    This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.

  • DISKUS™ powder inhalersDevice

    Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.

Study groups in NCT00363480
Study groupRoleWhat they receive
SFC 50/250 mcgExperimentalParticipants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
Receives: Drug: Salmeterol/Fluticasone 50/250 mcg; Drug: Salbutamol 100 mcg; Device: DISKUS™ powder inhalers

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12

    A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score >1 (Range: 0= None to 5= severe), rescue salbutamol use on <= 2 days and at most 4 occasions per week, and a morning peak flow >= 80% of the predicted value on each day per week. All of the criteria which includes no night-time awakenings due to asthma (diary entry), no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change are fulfilled. The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control.

    Measured: Week 9 to Week 12

Secondary outcomes (16)
  1. Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12

    The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. In order to derive the total ACT score, all 5 questions needed to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Measured: Baseline (Visit 3) and Week 12

  2. Change From Baseline in Mean ACT Score at Visit 6

    The total ACT score is based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms not under control. In order to derive the total ACT score, all 5 questions had to be answered. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Measured: Baseline (Viait 3) and Week 12

  3. Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12

    Well controlled or totally controlled asthma assessments were done according to the GOAL criteria. A week with well controlled asthma, when two or more of the criteria were fulfilled (diary entries): At most 2 days per week with 24-hour symptom score >1(Range: 0= None to 5= severe), rescue salbutamol use on <= 2 days and at most 4 occasions per week, and morning peak flow >= 80% of the predicted value on each day per week. All of the criteria which included no night-time awakenings due to asthma (diary entry),no emergency visits (diary entry), no exacerbations and no treatment-related adverse events leading to treatment change were fulfilled. The total ACT score was based on a range of 5 to 25. Higher score indicates better asthma control. A score of 19 or less may be a sign that asthma symptoms are not under control. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Measured: Week 12

  4. Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)

    For the level of asthma control, baseline values were derived taking the last 8 weeks during the pre-treatment period prior to Visit 3 into consideration. Regarding derived variables based on the asthma diary, data from the last week prior to Visit 3 was taken. Visit 3, regarded as baseline. AQLQ has 32 questions regarding activities, emotions, symptoms, and environmental triggers. Each item values range from 1 (maximum impairment) to 7 (no impairment). A positive change from baseline score indicates improvement.

    Measured: Baseline (Visit 3) up to Week 12

  5. Correlation of Change in AQLQ Score and Change in ACT Score

    Correlation between change in the AQLQ and ACT score was tabulated using the Pearson coefficient of correlation (linear correlation). The AQLQ contained 32 items in 4 domains: activity limitation, symptoms, emotional function and environmental stimuli. Scores for the domains as well as the overall score were scaled within a range of 1 (worst) to 7 (best).

    Measured: Week 12

  6. Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12

    FEV1, an amount of air exhaled by a person during a forced breath in one second. FEV1 assessed at Visit 1 and at Visits 3, 4, 5, 6. Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

    Measured: Baseline (Visit 3) up to Week 12

  7. Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12

    PEF, a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. The mean morning PEF evaluated by means of the data documented in the asthma diaries. Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Measured: Baseline (Visit 3) and Week 12

  8. Change From Baseline in Mean 24-hour Symptom Score at Week 12

    The various symptoms like wheezing, shortness of breath, coughing and chest tightness were assessed by the participants every morning using a symptom score scale which ranged from 0 (no symptoms during the past 24 hours) to 5 (symptoms so severe that participant could not go to work or carry out other normal daily activities). Change from baseline value was calculated by subtracting baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Measured: Baseline (Visit 3) and Week 12

  9. Change From Baseline in Number of Additional Usage of Salbutamol at Week 12

    Salbutamol was given as a rescue medicine, used on <= 2 days and at most 4 occasions per week. Change from baseline value was calculated by subtracting the baseline value from week 12 value. The assessments recorded at Visit 3 were considered as Baseline assessments.

    Measured: Baseline (Visit 3) and week 12

  10. Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12

    Number of nights with no night time awakening were recorded at Week 12. Baseline was the last corresponding time period immediately prior to Visit 3.

    Measured: Baseline (Visit 3) and week 12

  11. Number of Participants With Emergency Visits Due to Asthma

    Frequencies of emergency visits per participant were recorded during treatment period. Only the participants at risk were considered when calculating the incidence rates.

    Measured: Up to week 12

  12. Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment

    AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with AE who lead to change in asthma treatment were reported.

    Measured: Up to Week 12

  13. Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE

    An AE is any untoward medical occurrence in a participant or clinical AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. Number of participants with at least one treatment emergent serious and, non-serious AE were reported.

    Measured: Up to Week 12

  14. Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP were recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

    Measured: Baseline (Visit 3) up to Week 12

  15. Assessment of Tolerability by Change From Baseline of Pulse Rate

    Pulse rate was recorded over time (Visit 1, 3, 4, 5, and 6). Baseline was the measurement at Visit 3. Change from baseline value was calculated by subtracting baseline value from week 12 value.

    Measured: Baseline (Visit 3) up to Week 12

  16. Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements

    Frequencies of participants with at least one (near-) incident associated with peak flow measurements were recorded. analysis was done on safety population.

    Measured: Up to Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2006 (estimated)
  2. Study start17 May 2006
  3. Primary completion1 Sep 2007
  4. Study completion14 Sep 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
221 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00363480
Sponsor's protocol ID
SAM 106538
Status last verified
Mar 2018
First submitted
10 Aug 2006
Last updated
9 Mar 2018
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg and DISKUS™ powder inhalers in people with Asthma, run by GlaxoSmithKline at 32 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 32 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Mar 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12 (time frame: Week 9 to Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in